Skip to main content

Table 1 Characteristics of the entire study population and of hospital survivors, by AKI-RRT status

From: Acute kidney injury treated with renal replacement therapy and 5-year mortality after myocardial infarction-related cardiogenic shock: a nationwide population-based cohort study

 

Entire study population

Hospital survivors

Clinical featuresa

Total

No AKI-RRT

AKI-RRT

Total

No AKI-RRT

AKI-RRT

n = 5079 (100)b

n = 4417 (100)b

n = 662 (100)b

n = 3059 (100)b

n = 2805 (100)b

n = 254 (100)b

Sex

      

 Male

3388 (66.7)

2916 (66.0)

472 (71.3)

2164 (70.7)

1979 (70.6)

185 (72.8)

 Female

1691 (33.3)

1501 (34.0)

190 (28.7)

895 (29.3)

826 (29.4)

69 (27.2)

Age (years), median (IQR)

71 (62–78)

70 (62–78)

72 (65–77)

68 (60–75)

68 (60–75)

69 (60–74)

Age groups (years)

      

  < 60

1006 (19.8)

898 (20.3)

108 (16.3)

766 (25.0)

703 (25.1)

63 (24.8)

 60–69

1435 (28.3)

1247 (28.2)

188 (28.4)

966 (31.6)

886 (31.6)

80 (31.5)

 70–79

1724 (34.0)

1440 (32.6)

284 (42.9)

989 (32.3)

899 (32.1)

90 (35.4)

  ≥ 80

914 (18.0)

832 (18.8)

82 (12.4)

338 (11.1)

317 (11.3)

21 (8.3)

Comorbidities

      

 Congestive heart failure

330 (6.5)

281 (6.4)

49 (7.4)

166 (5.4)

145 (5.2)

21 (8.3)

 Peripheral vascular disease

556 (11.0)

475 (10.8)

81 (12.2)

299 (9.8)

268 (9.6)

31 (12.2)

 Cerebrovascular disease

585 (11.5)

504 (11.4)

81 (12.2)

307 (10.0)

284 (10.1)

23 (9.1)

 Chronic pulmonary disease

531 (10.5)

468 (10.6)

63 (9.5)

257 (8.4)

232 (8.3)

25 (9.8)

 Hypertension

1134 (22.3)

962 (21.8)

172 (26.0)

633 (20.7)

559 (19.9)

74 (29.1)

 Atrial fibrillation/flutter

393 (7.7)

342 (7.7)

51 (7.7)

185 (6.1)

166 (5.9)

19 (7.5)

 Venous thromboembolism

79 (1.6)

69 (1.6)

10 (1.5)

36 (1.2)

31 (1.1)

5 (2.0)

 Chronic kidney disease

177 (3.5)

129 (2.9)

48 (7.3)

95 (3.1)

67 (2.4)

28 (11.0)

 Liver disease

55 (1.1)

49 (1.1)

6 (0.9)

21 (0.7)

19 (0.7)

2 (0.8)

 Diabetes mellitusc

901 (17.7)

756 (17.1)

145 (22.0)

497 (16.3)

441 (15.7)

56 (22.1)

 Cancer

436 (8.6)

389 (8.8)

47 (7.1)

214 (7.0)

202 (7.2)

12 (4.7)

 Obesity

143 (2.8)

116 (2.6)

27 (4.1)

81 (2.7)

70 (2.5)

11 (4.3)

Medication used

      

 ACE inhibitors

1019 (20.1)

874 (19.8)

145 (21.9)

589 (19.3)

526 (18.8)

63 (24.8)

 Angiotensin II antagonists

666 (13.1)

578 (13.1)

88 (13.2)

413 (13.5)

379 (13.5)

34 (13.4)

 NSAIDS

654 (12.9)

551 (12.5)

103 (15.6)

383 (12.5)

346 (12.3)

37 (14.6)

In-hospital procedures

      

 CAG

3473 (68.4)

2979 (67.4)

494 (74.6)

2489 (81.4)

2290 (81.6)

199 (78.4)

 PCI

1873 (36.9)

1568 (35.5)

305 (46.1)

1185 (38.7)

1065 (38.0)

120 (47.2)

 CABG

1520 (29.9)

1334 (30.2)

186 (28.1)

1334 (43.6)

1251 (44.6)

82 (32.7)

  1. a Comorbidities registered as primary or secondary hospital inpatient and outpatient diagnoses within 10 years preceding current admission
  2. b Values are expressed as number (percentage) unless otherwise indicated
  3. c Defined as either a diagnosis code for diabetes or a prescription redemption for anti-diabetics within 100 days before MI admission
  4. d Prescription redemption within 100 days before admission
  5. ACE Angiotensin-converting enzyme, AKI-RRT Acute kidney injury treated with renal replacement therapy, CABG coronary artery bypass graft, CAG Coronary arteriography, IQR inter quartile range, NSAID non-steroidal anti-inflammatory drug, PCI percutaneous coronary arteriography